Search the Newsreel

AngioDynamics, Inc. $ANGO Shares Purchased by Lazard Asset Management LLC

Lazard Asset Management LLC significantly increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 1,328.2% during the first quarter, now owning 154,578 shares valued at $1.76 million. This comes as AngioDynamics exceeded Q1 earnings expectations, reporting an adjusted loss of $0.07 per share on $86.61 …

Mangoceuticals Has Until Feb. 1, 2027 to Meet Nasdaq's $1 Bid Rule

Mangoceuticals (NASDAQ: MGRX) has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, setting a new deadline of February 1, 2027. The company may consider a reverse stock split if necessary to meet the requirement, which involves …

Mangoceuticals Granted 180-Day Extension by Nasdaq to

Mangoceuticals Inc. (NASDAQ: MGRX) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to February 1, 2027. The company is simultaneously advancing its business combination with Nuclea Energy Inc., which is developing the Morpheus …

Mangoceuticals (NASDAQ: MGRX) wins more time on Nasdaq rules, advances Nuclea deal

Mangoceuticals (NASDAQ: MGRX) has secured an additional 180-day extension from Nasdaq to meet the minimum bid price requirement, pushing the deadline to February 1, 2027. This extension provides the company flexibility as it progresses with a definitive business combination agreement with Nuclea Energy Inc., …

Senior Vice President of Regulatory Affairs Warren Nighan Sold A Bunch Of Shares In AngioDynamics

Warren Nighan, Senior Vice President of Regulatory Affairs at AngioDynamics, recently sold US$344k worth of stock, representing 27% of his holding. While insiders did buy some shares in the last year, the overall trend points to more selling than buying. This sale, the largest …

TNG Therapeutics (TNGX) insider schedules 81,000-share option-related stock sale

Adam Crystal, an insider at TNG Therapeutics Inc. (TNGX), has filed a notice to sell 81,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, following the exercise of stock options, with an aggregate value of $2,201,580.00. This filing …

REG - Kavango Resources - Commissioning Commenced at Hillside Gold Project

Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by Janus Henderson Group PLC

AngioDynamics (NASDAQ: ANGO) insider plans $344K sale of equity awards

An insider at AngioDynamics (NASDAQ: ANGO) plans to sell 23,370 shares of common stock, valued at approximately $344,004.06. This proposed sale involves equity awards, specifically restricted stock from 2020 and performance share units from 2021, and will be conducted through Morgan Stanley Smith Barney …

Mangoceuticals, Inc. Common Stock (NASDAQ: MGRX) Stock Price, News & Analysis

Bango plc Revenue Breakdown – LSE:BGO

AngioDynamics (ANGO) SVP Warren Nighan Sells 23,370 Shares

Warren Nighan, SVP of Quality and Regulatory at AngioDynamics (ANGO), sold 23,370 shares for approximately $344,006. This transaction occurred on July 30, 2026, and leaves him with 64,745 shares. While the stock is deemed "Significantly Overvalued" by GuruFocus's GF Value model, institutional investors (gurus) …

Form 4 AngioDynamics Inc For: 31 July By Investing.com

This article reports on a Form 4 filing for AngioDynamics Inc. for July 31st. It provides various financial market data, including indices, commodities, bonds, and shares, along with trending stocks and investment strategy suggestions. The core content is the announcement of the Form 4 …

Angiodynamics SVP Warren Nighan Jr sells $344,006 in stock

Warren Nighan Jr., Senior Vice President at AngioDynamics Inc., sold 23,370 shares of company stock for a total of $344,006. This transaction occurred as the stock trades near its 52-week high after a 67% gain, with InvestingPro analysis suggesting it is overvalued. Despite the …

$Mangoceuticals (MGRX.US)$

The article is a single comment from a user named "Darnelle Taught Me" on the moomoo community feed, referencing Mangoceuticals (MGRX.US). It appears to be a user-generated post within a financial social media platform, with a disclaimer about educational purposes.

MGRX surges after Nuclea Energy reverse-merger deal reshapes company story

Mangoceuticals, Inc. (MGRX) stock surged 172.5% today following its definitive business combination agreement with Nuclea Energy. This reverse-merger transforms MGRX from a telehealth company into a speculative nuclear-power listing, attracting significant investor interest. Nuclea Energy, a developer of advanced nuclear technology, is expected to …

$Mangoceuticals (MGRX.US)$ sold a tad early. but definitely looking for another entry!

A moomoo Community user, MsNoFomoTrade, commented on the stock $Mangoceuticals (MGRX.US), stating they sold their shares a bit prematurely but are actively seeking another entry point. The post indicates investor interest in re-engaging with the stock despite a previous early exit.

AngioDynamics Inc (ANGO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AngioDynamics Inc (ANGO), highlighting its current risk score, industry ranking, and beta value. It details the stock's volatility, maximum drawdown, and return metrics over various periods, emphasizing its tendency to underperform in up-trending markets and experience smaller …

AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of AngioDynamics Inc (ANGO), stating its current valuation score is 7.33, ranking 152 out of 199 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -19.48, which is significantly below its recent high. It also …

Mangoceuticals agrees to merge with nuclear microreactor developer By Investing.com

Mangoceuticals, Inc. (NASDAQ:MGRX) has announced a definitive merger agreement with Nuclea Energy Inc., a nuclear technology company developing the Morpheus microreactor. Under the terms, Nuclea will become an indirect wholly owned subsidiary of Mangoceuticals, with Nuclea shareholders receiving exchangeable shares in Mangoceuticals. The transaction, …

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

Nuclea Energy Inc. has entered into a definitive business combination agreement with Mangoceuticals, Inc. to gain a Nasdaq public listing, aiming to fund the development and commercialization of its Morpheus microreactor. This move positions Nuclea to capitalize on the increasing demand for continuous, carbon-free …

Mangoceuticals (MGRX) plans merger giving Nuclea Energy 96% post-close stake

Mangoceuticals, Inc. (MGRX) has entered a definitive business combination agreement with Nuclea Energy Inc., where a newly formed Mangoceuticals subsidiary will amalgamate with Nuclea. This merger is intended to provide Nuclea a pathway to a Nasdaq public listing and significant capital access for developing …

Mangoceuticals (MGRX) plans Nuclea merger, 96% new-owner stake, $15M PIPE

Mangoceuticals (MGRX) has announced a Business Combination Agreement with Nuclea Energy Inc. through which Nuclea shareholders will own approximately 96% of the combined entity on a fully diluted basis before PIPE financing, with existing Mangoceuticals stockholders retaining about 4%. The transaction involves a two-stage …

Mangoceuticals to Combine With Nuclea Energy; Nuclea Holders to Own ~96% Pre-PIPE

Mangoceuticals (MGRX) has entered into a Business Combination Agreement with Nuclea Energy, utilizing a Canadian exchangeable-share structure. Upon closing, Nuclea shareholders will receive exchangeable shares in a Mango subsidiary, which can be exchanged for Mango common stock. Former Nuclea holders are expected to own …

Mangoceuticals Deal Would Put Nuclea's ~3.5-50 MWe Reactor on Nasdaq Path

Mangoceuticals (NASDAQ: MGRX) has signed a definitive business combination agreement with Nuclea Energy, a Canadian developer of the lead-cooled Morpheus microreactor, to advance next-generation nuclear microreactor technology. The deal is structured to provide Nuclea a Nasdaq listing and offer Mangoceuticals shareholders exposure to the …

Jacob D. Cohen to Leave CEO Role at Mangoceuticals, Becomes President in Consulting Role

Jacob D. Cohen, CEO of Mangoceuticals (MGRX), will step down from his CEO role upon the closing of a transaction, transitioning instead to President in an independent consulting capacity. New executive officers will be appointed by the Principal Nuclea Shareholders, and existing executives not …

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

Mangoceuticals, Inc. (NASDAQ: MGRX) has announced a definitive business combination agreement with Nuclea Energy Inc., a developer of advanced nuclear microreactor technology. This reverse merger will allow Nuclea to access public markets, aiming to capitalize on the increasing demand for continuous, carbon-free power driven …

Cango Inc (CANG) Institutional Confidence

Cango Inc (CANG) has an institutional shareholding score of 3.00, placing it 283 out of 485 in the Software & IT Services industry. The latest institutional shareholding proportion is 12.03%, marking a 68.12% quarter-over-quarter increase. While James Simons is listed as the largest institutional …

Contango Silver & Gold Inc. Revenue Breakdown – AMEX:CTGO

CANG|Cango Inc|Price:1.565|Chg%:-0.135

This article provides a detailed financial and analytical overview of Cango Inc (CANG). It highlights the company's strong fundamentals and growth potential, despite recent market performance not fully reflecting its underlying value. Analysts have rated CANG as a "Buy" with a significant upside potential, …

ANGO|AngioDynamics Inc|Price:14.630|Chg%:+0.290

This article provides a comprehensive stock analysis of AngioDynamics Inc (ANGO), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes high institutional ownership and a recent "Buy" rating from analysts with an expected …

AngioDynamics Number of Employees 2026 | Employee Count & Headcount Data

AngioDynamics, Inc. (ANGO) has 627 employees worldwide as of March 2026, marking a 2.8% decline since 2023 but a 0.1% increase year-over-year. The company is actively hiring, with 58 job postings in 2026, a 39.2% increase from 2025. Its workforce is concentrated in North …

REG - Contango HoldingsPLC - Results of General Meeting

Cango Inc (CANG) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cango Inc. (CANG), focusing on its price momentum, support and resistance levels, and key technical indicators. As of July 28, 2026, CANG has a price momentum score of 9.40, placing it first in its industry, and is …

Cango Inc (CANG) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Cango Inc (CANG), detailing its score of 1.28 within the Software & IT Services industry and a beta value of 0.75. It covers various risk metrics including volatility, maximum drawdown, return analysis, and liquidity. The report highlights …

AngioDynamics Inc (ANGO) Institutional Confidence

AngioDynamics Inc (ANGO) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 93.94%, a decrease of 11.97% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 3.06 million shares, despite a …